Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genentech
Biotech
Roche reports pivotal MS win, but deaths add to safety questions
The discovery that more patients died on fenebrutinib than on the control drug has spurred further analyses by Roche.
Nick Paul Taylor
Mar 2, 2026 6:00am
Roche unveils data behind BTK inhibitor's phase 3 MS win
Feb 9, 2026 7:00am
Genentech cut at least 489 jobs last year, new filing reveals
Feb 6, 2026 1:38pm
Roche continues RNA return with $1.7B deal for Sanegene drug
Feb 2, 2026 8:35am
Ollin eyes phase 3 after topping Vabysmo in early-stage trial
Jan 8, 2026 3:20pm
Addition Tx does the math and emerges from stealth with $100M
Dec 17, 2025 7:45am
